Agnes C Kant (Agnes Kant, A Kant)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 12

Top Topics

Coronavirus Disease

Electronic Health Record

Loop Mediated Isothermal Amplification

Top Venues

Journal of medical systems

British journal of clinical pharmacology

Pharmacoepidemiology and drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

H Abedian Kalkhoran, Juliette Zwaveling, Florence P A M van Hunsel, Agnes C Kant
An innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records. Journal of medical systems 48 (1) (2024)
H Abedian Kalkhoran, Juliette Zwaveling, Florence P A M van Hunsel, Agnes C Kant
An innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records. Journal of medical systems 48 (1) (2024)
H Abedian Kalkhoran, Juliette Zwaveling, Florence P A M van Hunsel, Agnes C Kant
An innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records. Journal of medical systems 48 (1) (2024)
Maud de Feijter, Marleen M H J van Gelder, Lieke C M Vissers, Agnes C Kant, Petra J Woestenberg
The risk of miscarriage after COVID-19 vaccination before and during pregnancy. Pharmacoepidemiology and drug safety (2023)
Agnes C Kant
Appeal for Increasing the Impact of Pharmacovigilance. Drug safety (2023)
Agnes C Kant
Appeal for Increasing the Impact of Pharmacovigilance. Drug safety 47 (2) (2023)
Agnes C Kant
Appeal for Increasing the Impact of Pharmacovigilance. Drug safety 47 (2) (2023)
Janneke W Duijster, M E Schoep, T E Nieboer, R Jajou, Agnes C Kant, F Van Hunsel
Menstrual abnormalities after COVID-19 vaccination in the Netherlands: a description of spontaneous and longitudinal patient-reported data. British journal of clinical pharmacology (2023)
Ingrid Oosterhuis, Joep H G Scholl, Eugene P van Puijenbroek, Agnes C Kant, Florence P A M van Hunsel
Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience. Drug safety (2022)
Agnes C Kant, Jurriaan Jansen, Leontine van Balveren, Florence P A M van Hunsel
Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands. Drug safety 45 (4) (2022)
Agnes C Kant, Florence P A M van Hunsel
Authors' Reply to Mungmunpuntipantip et al.'s Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands". Drug safety 45 (8) (2022)
Agnes C Kant, Florence van Hunsel, Eugene van Puijenbroek
Numbers of spontaneous reports: How to use and interpret? British journal of clinical pharmacology (2021)